Global Prothrombin Complex Concentrates Market 2026-2033

Rising Use in Emergency Bleeding Management and Expanding Hospital Adoption to Drive Prothrombin Complex Concentrates Market to USD 2,473.7 Mn by 2033 at 10.2% CAGR – Coherent Market Insights

Prothrombin Complex Concentrates Market – Driver

Growing demand for rapid anticoagulant reversal: The increasing use of oral anticoagulants for atrial fibrillation, venous thromboembolism, and stroke prevention is raising the incidence of anticoagulant-associated bleeding and the need for rapid reversal before emergency procedures. Prothrombin complex concentrates offer faster factor replacement with a lower infusion volume than plasma, supporting their adoption in emergency and surgical care. For instance, a 2026 study published in Transfusion reported that 4F-PCC achieved normal or mildly abnormal hemostasis in 89.8% of 59 patients receiving factor Xa inhibitors before urgent invasive procedures.

Expansion Into Broader Surgical-Bleeding Applications

Clinical development aimed at expanding PCC use beyond traditional warfarin reversal is expected to enlarge the addressable patient population. For instance, CSL’s product pipeline, updated on May 26, 2026, listed KCENTRA PCC in Phase III development for surgical settings involving a high risk of major bleeding. This development indicates increasing manufacturer investment in extending PCC use across cardiac, trauma, and other major surgical procedures.

Prothrombin Complex Concentrates Market – Opportunity

Expansion into perioperative and cardiac-surgery bleeding management

A significant market opportunity lies in extending four-factor PCC use beyond vitamin K antagonist reversal to coagulation-factor replacement during major surgeries. PCCs can potentially reduce reliance on fresh frozen plasma owing to their rapid administration and lower infusion volume. For instance, a randomized clinical study updated on June 24, 2026, is evaluating low-dose four-factor PCC against fresh frozen plasma for reducing perioperative blood loss in patients undergoing valvular heart surgery. Positive clinical evidence could support wider hospital adoption and future indication expansion. (Source: ClinicalTrial.gov)

Potential use for Direct Oral Anticoagulant-Associated Bleeding

The growing clinical investigation of PCCs for bleeding linked to factor Xa inhibitors presents an opportunity to expand their eligible patient population. For instance, on June 25, 2026, a Phase III study of Octaplex, updated, is assessing its hemostatic efficacy and safety in patients experiencing acute major bleeding while receiving factor Xa inhibitor therapy. Successful outcomes could strengthen the role of PCCs in emergency departments and trauma centres, although this application remains subject to clinical and regulatory validation.

Global Prothrombin Complex Concentrates Market, by Type (3-FactorPCC and 4-Factor PCC), by Application (Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, and Others), by End User (Hospital, Ambulatory Surgical Centres and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,253.4 Mn in 2026 and is expected to exhibit a CAGR of 10.2% over the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Prothrombin Complex Concentrates Market – Market Trends

Expansion of 4F-PCC into Cardiac and Complex Surgical Bleeding

Four-factor prothrombin complex concentrate is increasingly being evaluated beyond its established use in vitamin K antagonist reversal, particularly for controlling bleeding during complex cardiovascular surgery. As of May 26, 2026, CSL’s official development pipeline lists KCENTRA PCC for surgical bleeding as a Phase III program. In addition, the Phase III NCT07094087 study, updated in May 2026, is comparing 4F-PCC with fresh frozen plasma in adults undergoing complex cardiovascular surgery with cardiopulmonary bypass. Successful clinical outcomes could expand PCC utilization across cardiac operating rooms, intensive care units, and hospital blood-management programs.

Growing Use in Factor Xa Inhibitor-Associated Bleeding

Demand for 4F-PCC is increasing for the management of bleeding associated with oral factor Xa inhibitors such as apixaban and rivaroxaban. A 2026 peer-reviewed study reported that 4F-PCC achieved 72.6% hemostatic efficacy within 12 hours among patients with factor Xa inhibitor-associated acute major gastrointestinal bleeding. Another study published on April 2, 2026, evaluated 4F-PCC before urgent invasive procedures and found that thromboembolic events were infrequent. This evidence is encouraging broader emergency and perioperative use, although current U.S. FDA indications for Kcentra and Balfaxar remain focused on vitamin K antagonist reversal.

Late-Stage Clinical Development for DOAC Reversal

Manufacturers are investing in late-stage studies that could support standardized use of PCC products for direct oral anticoagulant-related bleeding. The Phase III OCTAPLEX study is evaluating low- and high-dose four-factor PCC in patients experiencing acute major bleeding while receiving factor Xa inhibitors, with final analysis planned for the second quarter of 2026. Positive results could facilitate treatment-protocol standardization, strengthen reimbursement discussions, and potentially support regulatory submissions for expanded indications. However, competition is also increasing, as investigational reversal agents such as TAK-330 are being compared directly with 4F-PCC in clinical development programs updated during 2026.

Adoption of Precision and Viscoelastic-Guided Dosing

Hospitals are moving toward more individualized PCC administration using point-of-care coagulation testing. A study published online in April 2026 evaluated the dose-dependent effects of 4F-PCC on rotational thromboelastometry clotting time among cardiac and aortic surgery patients. This reflects a shift from relying primarily on body weight and international normalized ratio toward viscoelastic-guided treatment decisions. More precise dosing may help hospitals control product consumption, reduce unnecessary administration, shorten treatment time, and balance hemostatic efficacy against thromboembolic risk.

Stronger Safety Monitoring and Risk-Based Product Selection

Safety surveillance is becoming increasingly important as PCC use expands into new bleeding indications. A 2026 study comparing PCC and fresh frozen plasma reported thromboembolic complications in 6.7% of PCC-treated patients and 9.4% of plasma-treated patients, with no statistically significant difference between the groups. In the activated PCC segment, the European Medicines Agency’s EUHASS pharmacovigilance study specifically monitors thromboembolism and thrombotic microangiopathy when activated PCC is used alongside emicizumab. These developments are encouraging hospitals to implement patient-risk assessment, controlled dosing, pharmacovigilance, and indication-specific procurement protocols.

Market implication

In 2026, the central market trend is the gradual transition of PCC—particularly 4F-PCC—from a specialized warfarin-reversal product toward a broader hospital-based bleeding-management therapy. Cardiac surgery, factor Xa inhibitor reversal, precision dosing, and evidence-based substitution of plasma represent the most important potential growth areas, subject to regulatory approval and continued safety validation.

To know the latest trends and insights prevalent in the Global Prothrombin Complex Concentrates Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/prothrombin-complex-concentrates-market-4647

Key Development

In May 2026, CSL advanced KCENTRA into Phase III development for surgical bleeding. The company’s pipeline lists KCENTRA, a four-factor prothrombin complex concentrate, for potential use in surgical settings with a high risk of major bleeding. This indication-expansion program represents an important innovation, as it could extend PCC use beyond conventional vitamin K antagonist reversal into broader perioperative bleeding management. (Source: CSL)
In March 2026, new clinical evidence supported the use of 4F-PCC in urgent orthopedic surgery. A Phase III post-hoc analysis involving 51 patients found rapid INR reduction in 43.3% of patients receiving 4F-PCC compared with 0.0% receiving plasma. Median time to surgery was also reduced to 5.8 hours from 19.2 hours, supporting wider adoption of PCC-based rapid anticoagulation reversal protocols. (Source: NCBI)

Key Takeaways of the Global Prothrombin Complex Concentrates Market

The global prothrombin complex concentrates market is expected to register a CAGR of 10.2% over the forecast period, driven by ongoing product innovation, clinical evaluation, and potential indication expansion. For instance, in 2026, CSL listed KCENTRA, a four-factor prothrombin complex concentrate, in its development pipeline for potential use in surgical settings involving a high risk of major bleeding, indicating continued efforts to expand the clinical application of PCC products.
Among end users, the hospital segment is expected to account for the largest market share of 82.0% in 2026, owing to the extensive use of PCCs in emergency departments, intensive care units, operating rooms, and trauma centres for rapid anticoagulation reversal and severe bleeding management. For instance, a ClinicalTrials.gov study updated in January 2026 at Strasbourg University Hospital evaluated the administration of PCC within the first 48 hours of hospital admission among patients experiencing gastrointestinal bleeding while receiving direct oral anticoagulants, highlighting the central role of hospitals in PCC utilization.

Key Players

Key players operating in the global prothrombin complex concentrates market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin